Tanezumab

DB12335InvestigationalProtein Based Therapies

Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.

Mechanism: Pharmacologically active on Beta-nerve growth factor
Curator reviewed
Code names: RN624

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

26Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 16 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tanezumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.